{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:33:07Z","timestamp":1791232387217,"version":"4.1.0"},"reference-count":46,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"abstract":"<jats:p>Recent molecular biology findings have shown that for the penetration of the SARS-CoV-2 coronavirus into host cells, a key role is played by protease serine 2, the activity of which is dependent on androgens. The important role of androgens is also evidenced by clinical observations that men in some age categories are infected by this novel coronavirus up to two times more frequently than women. In addition, men with androgenic alopecia tend to have more serious clinical courses, while men with androgen deprivation as a result of prostate cancer treatments tend to have milder courses. This is in line with the fact that preadolescent children are only rarely sickened with serious forms of SARS-CoV-2 infections. Even though these observations may be explained by other factors, many authors have hypothesized that lowered androgen levels and blocking their activity using anti-androgen medication may moderate the course of the viral infection in intermediately- to critically-affected cases. Clearly, it would be important for androgen deprivation to block not just gonadal androgens, but also adrenal androgens. On the other hand, low androgen levels are considered to be \na risk factor for the course of SARS-CoV-2 infections, either because low androgen levels have a general effect on anabolic-catabolic equilibrium and energy metabolism, or because of the ability of testosterone to modify the immune system. It is not yet clear if infection with this novel coronavirus might induce hypogonadism, leading to undesirable side effects on male fertility.<\/jats:p>","DOI":"10.33549\/physiolres.934724","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T10:34:31Z","timestamp":1639737271000},"page":"S145-S151","source":"Crossref","is-referenced-by-count":6,"title":["Androgens in SARS-CoV-2 Coronavirus Infections"],"prefix":"10.33549","author":[{"given":"L","family":"ST\u00c1RKA","sequence":"first","affiliation":[{"name":"Institute of Endocrinology, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"DU\u0160KOV\u00c1","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"19169","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"AL-LAMI RA, URBAN RJ, VOLPI E, ALGBURI AMA, BAILLARGEON J: Sex hormones and novel corona virus infectious disease (COVID-19). Mayo Clin Proc 95: 1710-1714, 2020. https:\/\/doi.org\/10.1016\/j.mayocp.2020.05.013","DOI":"10.1016\/j.mayocp.2020.05.013"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"CADEGIANI FA, GOREN A, WAMBIER CG: Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). Med Hypotheses 143: 110112, 2020. https:\/\/doi.org\/10.1016\/j.mehy.2020.110112","DOI":"10.1016\/j.mehy.2020.110112"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"CADEGIANI FA, LIM RK, GOREN A, MCCOY J, SITUM M, KOVACEVIC M, VA\u00d1\u00d3 GALV\u00c1N S, SINCLAIR R, TOSTI A, WAMBIER CG: Clinical symptoms of hyperandrogenic women diagnosed with COVID-19. J Eur Acad Dermatol Venereol 15: e101-e104, 2021. https:\/\/doi.org\/10.1111\/jdv.17004","DOI":"10.1111\/jdv.17004"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"CATTRINI C, BERSANELLI M, LATOCCA MM, CONTE B, VALLOME G, BOCCARDO F: Sex hormones and hormone therapy during COVID-19 pandemic: Implications for patients with cancer. Cancers (Basel) 12: 2325, 2020. https:\/\/doi.org\/10.3390\/cancers12082325","DOI":"10.3390\/cancers12082325"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"DUTTA S, SENGUPTA P: SARS-CoV-2 and male infertility: Possible multifaceted pathology Reprod Sci 28: 23-26, 2021. https:\/\/doi.org\/10.1007\/s43032-020-00261-z","DOI":"10.1007\/s43032-020-00261-z"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"GIAGULLI VA, GUASTAMACCHIA E, MAGRONE T, JIRILLO E, LISCO G, DE PERGOLA G, TRIGGIANI V: Worse progression of COVID-19 in men: Is testosterone a key factor? Andrology 9: 53-64, 2021. https:\/\/doi.org\/10.1111\/andr.12836","DOI":"10.1111\/andr.12836"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"GOREN A, MCCOY J, WAMBIER CG, VANO-GALVAN S, SHAPIRO J, DHURAT R, WASHENIK K, LOTTI T: What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy. Dermatol Ther 33: e13365, 2020a. https:\/\/doi.org\/10.1111\/dth.13365","DOI":"10.1111\/dth.13365"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"GOREN A, VA\u00d1O-GALV\u00c1N S, WAMBIER CG, MCCOY J, GOMEZ-ZUBIAUR A, MORENO-ARRONES OM, SHAPIRO J, SINCLAIR RD, GOLD MH, KOVACEVIC M, MESINKOVSKA NA, GOLDUST M, WASHENIK K: A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol 19: 1545-1547, 2020b. https:\/\/doi.org\/10.1111\/jocd.13443","DOI":"10.1111\/jocd.13443"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"GOREN A, WAMBIER CG, HERRERA S, MCCOY J, VA\u00d1O-GALV\u00c1N S, GIOIA F, COMECHE B, RON R, SERRANO-VILLAR S, RAMOS PM, CADEGIANI FA, KOVACEVIC M, TOSTI A, SHAPIRO J, SINCLAIR RJ: Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. J Eur Acad Dermatol Venereol 35: e13-e15, 2021c. https:\/\/doi.org\/10.1111\/jdv.16953","DOI":"10.1111\/jdv.16953"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"GRUBIC KEZELE T: Androgen-driven COVID-19 infection - is testosterone an enemy or a friend? Hormone Mol Biol Clin Invest 41: 20200027, 2020. https:\/\/doi.org\/10.1515\/hmbci-2020-0027","DOI":"10.1515\/hmbci-2020-0027"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"GURWITZ D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res 81: 537-540, 2020. https:\/\/doi.org\/10.1002\/ddr.21656","DOI":"10.1002\/ddr.21656"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"HAGHPANAH A, MASJEDI F, ALBORZI S, HOSSEINPOUR A, DEHGHANI A, MALEKMAKAN L, ROOZBEH J: Potential mechanisms of SARS.CoV-2 action on male gonadal function and fertility. Current status and future prospects. Andrologia 53: e13883, 2021. https:\/\/doi.org\/10.1111\/and.13883","DOI":"10.1111\/and.13883"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"HOFFMANN M, KLEINE-WEBER H, SCHROEDER S: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181: 271-280, 2020. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"HUSSAIN AN, HUSSAIN F, HAS HMI SK: Role of testosterone in COVID-19 patients - A double-edged sword? Med Hypotheses 144: 110287, 2020. https:\/\/doi.org\/10.1016\/j.mehy.2020.110287","DOI":"10.1016\/j.mehy.2020.110287"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"JONES AL, JAEGER B, SCHILD C: No credible evidence for links between 2D:4D and covid outcomes: A probabilistic perspective on digit ratio, ACE variants, and national case fatalities. Early Hum Dev 152: 105272, 2021. https:\/\/doi.org\/10.1016\/j.earlhumdev.2020.105272","DOI":"10.1016\/j.earlhumdev.2020.105272"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"KADIHASANOGLU M, AKTAS S, YARDIMCI E, ARAL H, KADIOGLU A: SARS-CoV-2 pneumonia affects male reproductive hormone levels: A prospective, cohort study. J Sex Med 18: 256-264, 2021. https:\/\/doi.org\/10.1016\/j.jsxm.2020.11.007","DOI":"10.1016\/j.jsxm.2020.11.007"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"KARLBERG J, CHONG DSY, LAI WYY: Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? Am J Epidemiol 159: 229-231, 2004. https:\/\/doi.org\/10.1093\/aje\/kwh056","DOI":"10.1093\/aje\/kwh056"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"KLEIN EA, LI J, MILINOVICH A, SCHOLD JD, SHARIFI N, KATTAN MW, JEHI L: Androgen deprivation therapy in men with prostate cancer does not affect risk of infection with SARS-CoV-2. J Urol 205: 441-443, 2021. https:\/\/doi.org\/10.1097\/JU.0000000000001338","DOI":"10.1097\/ju.0000000000001338"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"LA VIGNERA S, CANNARELLA R, CONDORELLI RA: Sex-specific SARS-CoV-2 mortality: among hormone-modulated ACE2 expression, risk of venous thromboembolism and hypovitaminosis D. Int J Mol Sci 21: 2948, 2020. https:\/\/doi.org\/10.3390\/ijms21082948","DOI":"10.3390\/ijms21082948"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"LUCAS JM, HEINLEIN C, KIM T: The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov 4: 1310-1325, 2014. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-1010","DOI":"10.1158\/2159-8290.cd-13-1010"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"MANNING JT, FINK B: Understanding COVID-19: digit ratio (2D:4D) and sex differences in national case fatality rates. Early Hum Dev 146: 105074, 2020. https:\/\/doi.org\/10.1016\/j.earlhumdev.2020.105074","DOI":"10.1016\/j.earlhumdev.2020.105074"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"MCCOY J, WAMBIER CG, VANO-GALVAN S, SHAPIRO J, SINCLAIR R, RAMOS PM, WASHENIK K, ANDRADE M, HERRERA S, GOREN A: Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19? J Cosmet Dermatol 19: 1542-1543, 2020. https:\/\/doi.org\/10.1111\/jocd.13455","DOI":"10.1111\/jocd.13455"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"MONTOPOLI M, ZUMERLE S, VETTOR R, RUGGE M, ZORZI M, CATAPANO CV, CARBONE GM, CAVALLI A, PAGANO F, RAGAZZI E, PRAYER-GALETTI T, ALIMONTI A: Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol 31: 1040-1045, 2020. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.479","DOI":"10.1016\/j.annonc.2020.04.479"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"MORGANTE G, TROIA L, DE LEO V: Coronavirus disease 2019 (SARS-CoV-2) and polycystic ovarian disease: Is there a higher risk for these women? J Steroid Biochem Mol Biol 205: 105770, 2021. https:\/\/doi.org\/10.1016\/j.jsbmb.2020.105770","DOI":"10.1016\/j.jsbmb.2020.105770"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"OK\u00c7ELIK S: COVID-19 pneumonia causes lower testosterone levels. Andrologia 53: e13909, 2021. https:\/\/doi.org\/10.1111\/and.13909","DOI":"10.1111\/and.13909"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"PACES J, STRIZOVA Z, SMRZ D, CERNY J: COVID-19 and the immune system. Physiol Res 69: 379-388, 2020. https:\/\/doi.org\/10.33549\/physiolres.934492","DOI":"10.33549\/physiolres.934492"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"PAPADOPOULOS V, LI L, SAMPLASKI M: Why does COVID-19 kill more elderly men than women? Is there a role for testosterone? Andrology 9: 65-72, 2021. https:\/\/doi.org\/10.1111\/andr.12868","DOI":"10.1111\/andr.12868"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"POZZILLI P, LENZI A: Commentary: Testosterone, a key hormone in the context of COVID-19 pandemic. Metabolism 108: 154252, 2020. https:\/\/doi.org\/10.1016\/j.metabol.2020.154252","DOI":"10.1016\/j.metabol.2020.154252"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"RAMBHATLA A, BRONKEMA CJ, CORSI N, KEELEY J, SOOD A, AFFAS Z, DABAJA AA, ROGERS CG, LIROFF SA, ABDOLLAH F: COVID-19 Infection in men on testosterone replacement therapy. J Sex Med 18: 215-218, 2021. https:\/\/doi.org\/10.1016\/j.jsxm.2020.09.013","DOI":"10.1016\/j.jsxm.2020.09.013"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"RASTRELLI G, DI STASI V, INGLESE F, BECCARIA M, GARUTI M, DI COSTANZO D, SPREAFICO F, GRECO GF, CERVI G, PECORIELLO A, MAGINI A, TODISCO T, CIPRIANI S, MASEROLI E, CORONA G, SALONIA A, LENZI A, MAGGI M, DE DONNO G, VIGNOZZI L: Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. Andrology 9: 88-98, 2021. https:\/\/doi.org\/10.1111\/andr.12821","DOI":"10.1111\/andr.12821"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"ROWLAND SP, O'BRIEN BERGIN E: Screening for low testosterone is needed for early identification and treatment of men at high risk of mortality from Covid-19. Crit Care 24: 367, 2020. https:\/\/doi.org\/10.1186\/s13054-020-03086-z","DOI":"10.1186\/s13054-020-03086-z"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"RUAN Y, HU B, LIU Z, LIU K, JIANG H, LI H, LI R, LUAN Y, LIU X, YU G, XU S, YUAN X, WANG S, YANG W, YE Z, LIU J, WANG T: No detection of SARS-CoV-2 from urine, expressed prostatic secretion, and semen in 74 recovered COVID-19 male patients: A perspective and urogenital evaluation. Andrology 9: 99-106, 2021. https:\/\/doi.org\/10.1111\/andr.12939","DOI":"10.1111\/andr.12939"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"SANSONE A, MOLLAIOLI D, CIOCCA G, LIMONCIN E, COLONNELLO E, VENA W, JANNINI EA: Addressing male sexual and reproductive health in the wake of COVID-19 outbreak. J Endocrinol Invest 44: 223-231, 2021. https:\/\/doi.org\/10.1007\/s40618-020-01350-1","DOI":"10.1007\/s40618-020-01350-1"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"SHI Y, WANG Y, SHAO C: COVID-19 infection: the perspectives on immune responses. Cell Death Differ 27: 1451-1454, 2020. https:\/\/doi.org\/10.1038\/s41418-020-0530-3","DOI":"10.1038\/s41418-020-0530-3"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"\u0160IMKOV\u00c1 M, V\u00cdTK\u016e J, KOL\u00c1TOROV\u00c1 L, VRB\u00cdKOV\u00c1 J, VOS\u00c1TKOV\u00c1 M, V\u010cEL\u00c1K J, DU\u0160KOV\u00c1 M: Endocrine disruptors, obesity, and cytokines - How relevant are they to PCOS? Physiol Res 69 (Suppl 2): S279-S293, 2020. https:\/\/doi.org\/10.33549\/physiolres.934521","DOI":"10.33549\/physiolres.934521"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"ST\u00c1RKA L, DU\u0160KOV\u00c1 M, POSP\u00cd\u0160ILOV\u00c1 H, HILL M: Estradiol, obesity and hypogonadism. Physiol Res 69 (Suppl 2): S273-S278, 2020a. https:\/\/doi.org\/10.33549\/physiolres.934510","DOI":"10.33549\/physiolres.934510"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"ST\u00c1RKA L, V\u00cdTK\u016e J, DU\u0160KOV\u00c1 M: 11-Keto-testosterone and other androgens of adrenal origin. Physiol Res 69 (Suppl 2): S187-S192, 2020b. https:\/\/doi.org\/10.33549\/physiolres.934516","DOI":"10.33549\/physiolres.934516"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"SUBRAMANIAN A, ANAND A, ADDERLEY N, OKOTH K, TOULIS KA, GOKHALE K, SAINSBURY C, O'REILLY MW, WIEBKE A, NIRANTHARAKUMAR K: Increased COVID-19 infections in women with polycystic ovary syndrome: a population-based study. Eur J Endocrinol 184: 637-645, 2021. https:\/\/doi.org\/10.1530\/EJE-20-1163","DOI":"10.1530\/eje-20-1163"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"VA\u0160K\u016e A: Covid-19 infection and the host genetic predisposition: does it exist? Physiol Res 69: 511-514, 2020. https:\/\/doi.org\/10.33549\/physiolres.934504","DOI":"10.33549\/physiolres.934504"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"WADMAN M: Sex hormones signals why virus hits men harder. Science 368: 1038-1039, 2020. https:\/\/doi.org\/10.1126\/science.368.6495.1038","DOI":"10.1126\/science.368.6495.1038"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"WAMBIER C, GOREN A: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated. J Am Acad Dermatol 83: 308-309, 2020a. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.032","DOI":"10.1016\/j.jaad.2020.04.032"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"WAMBIER CG, VA\u00d1O-GALV\u00c1N S, MCCOY J, GOMEZ-ZUBIAUR A, HERRERA S, HERMOSA-GELBARD \u00c1, MORENO-ARRONES OM, JIM\u00c9NEZ-G\u00d3MEZ N, GONZ\u00c1LEZ-CANTERO A, FONDA-PASCUAL P, SEGURADO-MIRAVALLES G, SHAPIRO J, P\u00c9REZ-GARC\u00cdA B, GOREN A: Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The \"Gabrin sign\". J Am Acad Dermatol 83: 680-682, 2020b. https:\/\/doi.org\/10.1016\/j.jaad.2020.05.079","DOI":"10.1016\/j.jaad.2020.05.079"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"WAMBIER CG, GOREN A, VA\u00d1O-GALV\u00c1N S, RAMOS PM, OSSIMETHA A, NAU G, HERRERA S, MCCOY J: Androgen sensitivity gateway to COVID-19 disease severity. Drug Dev Drug Dev Res 81: 771-776, 2020. https:\/\/doi.org\/10.1002\/ddr.21688","DOI":"10.1002\/ddr.21688"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"WENHAM C, SMITH J, MORGAN R: COVID-19: The gendered impact of the outbreak. Lancet 395: 846-848, 2020. https:\/\/doi.org\/10.1016\/S0140-6736(20)30526-2","DOI":"10.1016\/s0140-6736(20)30526-2"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"XU H, WANG Z, FENG C, YU W, CHEN Y, ZENG X, LIU C: Effects of SARS-CoV-2 infection on male sex-related hormones in recovering patients. Andrology 9: 107-114, 2021. https:\/\/doi.org\/10.1111\/andr.12942","DOI":"10.1111\/andr.12942"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"YOUNIS JS, SKORECI K, ABASSI Z: The double edge sword of testosterone's role in the COVID-19 pandemic. Front Endocrinol (Lausanne) 12: 607179, 2021. https:\/\/doi.org\/10.3389\/fendo.2021.607179","DOI":"10.3389\/fendo.2021.607179"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T10:34:35Z","timestamp":1639737275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2021\/70_S145.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":46,"URL":"https:\/\/doi.org\/10.33549\/physiolres.934724","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,14]]}}}